PFE PFIZER INC
Pharmaceutical Preparations · NYSE · SEC CIK 78003 · Fiscal year ends 12/31
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.3%
TTM net income YoY-59.0%
TTM EPS YoY-59.3%
Revenue 3-yr CAGR-2.8%
Net income 3-yr CAGR-27.3%
Margins
Gross margin73.4%
Operating margin—
Net margin6.3%
FCF margin18.5%
EBITDA margin—
Returns
ROE4.4%
ROA2.0%
ROIC (approx.)—
Asset turnover0.31x
Leverage & solvency
Liabilities / assets56.3%
Debt / equity0.70x
Current ratio1.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.51x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-27 | 2026Q22026-06-28 | 2026Q12026-03-29 | 2025Q4*2025-12-31 | 2025Q32025-09-28 | 2025Q22025-06-29 | 2025Q12025-03-30 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $16.58B | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B | $13.71B | $17.76B |
| Cost of revenue | $4.03B | $4.09B | $3.55B | $5.27B | $4.17B | $3.78B | $2.85B | $5.91B |
| Gross profit | $12.55B | $10.94B | $10.90B | $12.29B | $12.48B | $10.88B | $10.87B | $11.85B |
| R&D expense | $3.02B | $2.81B | $2.49B | $3.21B | $2.55B | $2.48B | $2.20B | $3.04B |
| SG&A expense | $3.28B | $3.41B | $2.96B | $4.16B | $3.19B | $3.42B | $3.03B | $4.27B |
| Interest expense | $662.00M | $667.00M | $668.00M | $711.00M | $652.00M | $654.00M | $654.00M | $739.00M |
| Pretax income | $3.38B | -$653.00M | $3.17B | -$1.64B | $3.33B | $3.04B | $2.79B | -$10.00M |
| Income tax | $134.00M | -$407.00M | $461.00M | -$2.00M | -$216.00M | $141.00M | -$189.00M | -$421.00M |
| Net income | $3.24B | -$248.00M | $2.69B | -$1.65B | $3.54B | $2.91B | $2.97B | $410.00M |
| EPS (basic) | 0.57 | -0.04 | 0.47 | — | 0.62 | 0.51 | 0.52 | — |
| EPS (diluted) | 0.56 | -0.04 | 0.47 | — | 0.62 | 0.51 | 0.52 | — |
| Dividends declared per share | 0.00 | 0.86 | 0.00 | 0.86 | 0.00 | 0.86 | 0.00 | 0.85 |
| Weighted avg. shares (diluted) | 5.75B | 5.70B | 5.73B | — | 5.71B | 5.71B | 5.71B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.82B | $976.00M | $1.70B | $1.14B | $1.39B | $1.69B | $1.48B | $1.11B |
| Short-term investments | $9.12B | $7.28B | $8.19B | $9.18B | $10.12B | $9.53B | $13.95B | $10.88B |
| Receivables | $14.19B | $12.49B | $12.59B | $11.87B | $14.26B | $12.08B | $11.85B | $11.46B |
| Inventory | $10.02B | $9.95B | $10.67B | $10.65B | $11.47B | $11.67B | $10.85B | $10.85B |
| Current assets | $45.01B | $41.36B | $42.82B | $42.90B | $46.92B | $43.70B | $45.86B | $50.36B |
| PP&E, net | $19.05B | $19.03B | $19.40B | $19.32B | $18.88B | $18.78B | $18.35B | $18.39B |
| Goodwill | $71.46B | $71.42B | $71.41B | $71.26B | $69.10B | $69.00B | $68.44B | $68.53B |
| Intangibles | $45.96B | $47.05B | $52.56B | $53.73B | $51.32B | $52.70B | $53.98B | $55.41B |
| Total assets | $204.54B | $201.13B | $207.62B | $208.16B | $208.73B | $206.09B | $208.03B | $213.40B |
| Current liabilities | $31.73B | $32.65B | $34.35B | $36.98B | $36.60B | $37.73B | $36.45B | $42.99B |
| Short-term debt | $2.67B | $2.70B | $3.89B | $3.15B | $4.30B | $4.29B | $4.47B | $6.95B |
| Long-term debt | $60.00B | $60.49B | $60.56B | $61.64B | $57.41B | $57.50B | $57.64B | $57.41B |
| Total debt | $62.67B | $63.19B | $64.45B | $64.80B | $61.71B | $61.80B | $62.11B | $64.35B |
| Total liabilities | $115.24B | $115.64B | $117.21B | $121.39B | $115.64B | $117.08B | $117.39B | $124.90B |
| Shareholders' equity | $89.00B | $85.19B | $90.10B | $86.48B | $92.80B | $88.69B | $90.34B | $88.20B |
| Net debt | $60.85B | $62.22B | $62.75B | $63.65B | $60.32B | $60.10B | $60.63B | $63.24B |
| Cash flow statement | ||||||||
| Operating cash flow | $5.38B | $835.00M | $2.62B | $5.35B | $4.60B | -$582.00M | $2.33B | $6.72B |
| Capital expenditure | $573.00M | $533.00M | $436.00M | $845.00M | $602.00M | $618.00M | $564.00M | $917.00M |
| Free cash flow | $4.80B | $302.00M | $2.18B | $4.50B | $4.00B | -$1.20B | $1.77B | $5.80B |
| Investing cash flow | -$2.03B | $2.11B | $785.00M | -$6.15B | -$2.43B | $3.95B | $3.27B | -$1.62B |
| Financing cash flow | -$2.51B | -$3.66B | -$2.86B | $596.00M | -$2.48B | -$3.20B | -$5.23B | -$5.11B |
| Depreciation & amortization | $1.58B | $1.62B | $1.61B | $1.69B | $1.66B | $1.62B | $1.62B | $1.79B |
| Stock-based compensation | $362.00M | $249.00M | $272.00M | $225.00M | $201.00M | $203.00M | $170.00M | $177.00M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.